CTX — Crescita Therapeutics Income Statement
0.000.00%
Last trade - 00:00- CA$11.02m
- CA$2.58m
- CA$19.58m
- 67
- 76
- 49
- 69
Annual income statement for Crescita Therapeutics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 15.6 | 16.8 | 23.5 | 17.5 | 19.6 |
| Cost of Revenue | |||||
| Gross Profit | 11 | 9.69 | 13.2 | 10.4 | 9.61 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 15.3 | 17.5 | 22.9 | 19.1 | 22.8 |
| Operating Profit | 0.344 | -0.773 | 0.631 | -1.53 | -3.21 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 0.52 | -1.01 | 0.404 | -1.53 | -2.76 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 0.037 | -1.1 | 0.862 | -1.99 | -2.75 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 0.037 | -1.1 | 0.862 | -1.99 | -2.75 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 0.037 | -1.1 | 0.862 | -1.99 | -2.75 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.009 | -0.088 | 0.041 | -0.098 | -0.138 |